ClinicalTrials.gg
Not yet recruitingNCT07121686Updated Aug 13, 2025

Effect of Red and Blue Light Irradiation on Wound Healing After Hemorrhoid Surgery

An interventional study of Red light exposure and Red-blue light exposure in Hemorrhoids, sponsored by The Affiliated Hospital of Putian University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by The Affiliated Hospital of Putian University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The subjects of this study were patients who took mixed haemorrhoidectomy during the period of December 2024 - December 2025 . The haemorrhoidectomy patients were randomly divided into routine group, red light group and red and blue light group, and were given different ways of trauma care, and the number of cases in each group was 105 , with a total of 305 cases. Observe the difference between red and blue light irradiation and routine care on the healing time of postoperative trauma and postoperative complications after haemorrhoidectomy, and evaluate the patients' quality of life and satisfaction with treatment under both red light irradiation and routine care.

Read the detailed description

The subjects of this study were patients who took mixed haemorrhoidectomy during the period of December 2024 - December 2025 . The diagnostic criteria were haemorrhoidal disease diagnosed as degree III-IV according to Goligher's classification. Inclusion criteria were 18 years \< age \< 75 years; diagnosis of haemorrhoids; internal haemorrhoid ligation + external haemorrhoidectomy. Exclusion criteria were patients with psychiatric disorders; patients with chronic diseases such as diabetes mellitus, hypertension and coronary artery disease; patients who underwent other treatments in addition to haemorrhoidectomy such as haemorrhoidal radiofrequency ablation/ sclerotherapy; patients who were unable to cooperate with the follow-up; and patients with perianal abscess, anal fissure, anal fistulae, and anorectal papillae hypertrophy. The haemorrhoidectomy patients were randomly divided into the conventional group, the red light group and the red and blue light group, and were given different ways of trauma care, and the number of cases in each group was 105 , with a total of 305 cases. The control group was given routine potassium permanganate sitz bath and routine care after internal haemorrhoid ligation + external haemorrhoidectomy to encourage patients to carry out functional exercise in moderation, mainly for anal lifting, buttock lifting and abdominal massage, etc.; the red light group was based on the control group, using red light irradiation for traumatic treatment; the red and blue light group was based on the control group, using red and blue light irradiation for traumatic treatment. Observe the difference between red and blue light irradiation and routine care on the healing time of postoperative trauma and postoperative complications after haemorrhoid surgery, and evaluate the patients' quality of life and satisfaction with treatment under both red light irradiation and routine care. Specific research content is to collect the postoperative data of the three groups of patients, including the recording of surgery-related pain scores, respectively, before the red light intervention and after the intervention of 1 d, 2 d, 3 d, 5 d, 7 d using visual analogue scoring (VAS) to assess the intensity of the patient's pain; the recording of the length of hospital stay; the recording of the degree of oedema of the anal verge were assessed before the red light intervention and after the intervention of 1 d, 2 d, 3 d, 5 d, 7 d, respectively, 0 Score 0: no oedema or slight oedema on the wound, but no impact on life. Score 2: oedema is present in only one area of the wound and is less than 1 cm in diameter, affecting daily activities. 4 points: multiple oedemas with a diameter of 1-2 cm, affecting daily activities. 6 points: multiple oedemas with a diameter of more than 2 cm, seriously affecting daily activities; follow up on the time to complete healing of the wound, quality of life scores, and the patient's satisfaction with the treatment.

02

Conditions studied

  • Hemorrhoids

Browse trials for

03

In context

Hemorrhoids

238 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

This study's planned enrollment of 315 is above the median of 100 across 183 interventional studies indexed under Hemorrhoids.

Browse Hemorrhoids studies →

Lead sponsor

The Affiliated Hospital of Putian University is the lead sponsor of 14 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75 years
  • Diagnosed with Grade III-IV hemorrhoids according to Goligher classification
  • Scheduled to undergo rubber band ligation of internal hemorrhoids + external hemorrhoidectomy
  • Willing and able to provide written
  • Able to comply with postoperative follow-up and treatment protocol

Exclusion criteria

Exclusion Criteria:

  • Psychiatric disorders or cognitive impairment
  • Uncontrolled chronic diseases:
  • Diabetes ( >7.5%)
  • Hypertension (BP >160/100 mmHg)
  • Coronary artery disease ( Class III-IV heart failure)
  • Concurrent other hemorrhoid treatments (e.g., radiofrequency ablation/sclerotherapy)
  • Inability to complete follow-up (e.g., living too far away, no stable contact)
  • Concurrent anal disorders:
  • Perianal abscess
  • Anal fissure
  • Anal fistula
  • Hypertrophied anal papilla
  • Pregnancy or lactation (for female patients)
  • History of phototherapy allergy
  • Participation in other clinical trials within 3 months

For registration, simply copy this structured list directly into the PRS system's eligibility section. The clear formatting will facilitate efficient review.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
315 participants (estimated)

Study arms

  • No intervention
    Conventional Care Group

    Standard postoperative care for hemorrhoidectomy patients.

  • Experimental
    Red Light Therapy Group

    Conventional care plus red light phototherapy.

    Device: Red light exposure

  • Experimental
    Red-Blue Light Therapy Group

    Conventional care plus combined red-blue light phototherapy.

    Device: Red-blue light exposure

Interventions

  • DeviceRed light exposure

    Patients in the red light group received red light therapy concurrently with standard care.

  • DeviceRed-blue light exposure

    Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care.

06

What researchers measure

Primary outcomes

  1. Wound healing time

    Defined as 100% re-epithelialization assessed by blinded evaluator

    Time frame: Daily from Day 1 until complete epithelialization (max 28 days post-op)

Secondary outcomes

  1. Postoperative pain intensity (VAS score)

    Assessed at rest and during defecation

    Time frame: Baseline, Day 1, 2, 3, 5, 7, and Day 14±2

  2. Perianal edema severity (0-6 scale)

    Evaluated by trained research nurses

    Time frame: Day 1, 2, 3, 5, 7, and Day 14±2

  3. Length of hospital stay

    Measured in hours with standardized discharge criteria

    Time frame: From surgery end to discharge (up to 7 days)

  4. Complication incidence

    Classified by Clavien-Dindo grading system

    Time frame: Within 30 days postoperatively

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07121686
Lead sponsor
The Affiliated Hospital of Putian University
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Aug 13, 2025

Study contacts

Chenxing C Jian, doctoral
Contact
ptyyjcx@126.com
86-139559538950

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion